Abstract
This phase I trial studies the side effects and best dose of trametinib and everolimus in
treating pediatric and young adult patients with low grade gliomas that has come back
(recurrent). Trametinib acts by targeting a protein in cells called MEK and disrupting tumor
growth. Everolimus is a drug that may block another pathway in tumor cells that can help
tumors grow. Giving trametinib and everolimus may work better to treat low grade gliomas
compared to trametinib or everolimus alone.
